Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paul Hartmann AGSTU:PHH2 64 Return-on-Tangible-Equity is 10.23% as of Dec. 2025, which is 17% below its 10-year median of 12.37. GuruFocus rates STU:PHH2 with a GF Score™ of 64/100 and a GF Value™ of €227.55 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 57.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Paul Hartmann AG's annualized net income for the quarter that ended in Dec. 2025 was €91 Mil. Paul Hartmann AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €887 Mil. Therefore, Paul Hartmann AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 10.23%.
The historical rank and industry rank for Paul Hartmann AG's Return-on-Tangible-Equity or its related term are showing as below:
STU:PHH2'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.45 Med: 12.37 Max: 15.09
Current: 6.92
During the past 13 years, Paul Hartmann AG's highest Return-on-Tangible-Equity was 15.09%. The lowest was 3.45%. And the median was 12.37%.
STU:PHH2's Return-on-Tangible-Equity is ranked better than 57.58% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs STU:PHH2: 6.92
Paul Hartmann AG (STU:PHH2) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Paul Hartmann AG Return-on-Tangible-Equity Related Terms
Paul Hartmann AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHH2 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.23% mean?
Paul Hartmann AG (STU:PHH2) has a Return-on-Tangible-Equity of 10.23% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Paul Hartmann AG and its competitors. This is 17% below median its historical median of 12.37. Over the past decade, Paul Hartmann AG's Return-on-Tangible-Equity has ranged from 3.45 to 15.09. According to the industry distribution chart, Paul Hartmann AG ranks #322 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 42.4%.
Is Paul Hartmann AG's Return-on-Tangible-Equity too high?
Paul Hartmann AG's current Return-on-Tangible-Equity of 10.23% is 17% below median its 10-year median of 12.37. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 15.09. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. Paul Hartmann AG's value of 10.23% is 153.2% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #322 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #322 out of 759 companies for Return-on-Tangible-Equity. This puts Paul Hartmann AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.04. Paul Hartmann AG's value of 10.23% is 153.2% above this benchmark. Historically, Paul Hartmann AG's own Return-on-Tangible-Equity has ranged from 3.45 to 15.09 over the past decade. While the company's 10-year median is 12.37 vs. the industry median of 4.04, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current Return-on-Tangible-Equity of 10.23% is 153.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current Return-on-Tangible-Equity is 10.23%, which is 17% below median its own 10-year median of 12.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €227.55, compared to a current price of €202.00 — trading 11.2% below its estimated fair value. The current Return-on-Tangible-Equity is 10.23%, which is 17% below median its 10-year median of 12.37 and 153.2% above the Medical Devices & Instruments industry median of 4.04. Paul Hartmann AG's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current Return-on-Tangible-Equity is 10.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €202.00 is trading 11.2% below its estimated GF Value™ of €227.55.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for STU:PHH2:
Return-on-Tangible-Equity: 10.23% (17% below median its 10-year median of 12.37)
GF Value™: €227.55 vs. price of €202.00 (11.2% below fair value)
Industry Position: 153.2% above the Medical Devices & Instruments median (#322 of 759)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
64GF Score
Get the complete analysis for STU:PHH2
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
